December 10, 2019 Comments Off on Aratana Therapeutics Inc. Lawsuits Blog, Current Investigations, Securities Fraud

Aratana Therapeutics Inc. Lawsuits

Aratana Therapeutics Inc. Lawsuits, featured by Top Securities Fraud Attorneys, The White Law Group

Aratana Therapeutics Inc. Investment Losses

Have you suffered losses investing in Aratana Therapeutics Inc.? If so, the securities attorneys at The White Law Group may be able to help you by filing a FINRA Dispute Resolution claim against the brokerage firm that sold you the investment.

Aratana Therapeutics Inc., a biopharmaceutical company, focuses on developing and commercializing innovative therapeutics for dogs and cats.

According to a press announcement in June 2019, shareholders of Aratana Therapeutics, Inc. (NASDAQ GM: PETX) common stock have filed a class action lawsuit in connection with the proposed acquisition of Aratana by Elanco Animal Health Incorporated announced on April 26, 2019.  The complaint alleges that in order to secure shareholder support for the Proposed Transaction, defendants allegedly issued materially incomplete disclosures in a registration statement Securities and Exchange Commission.  The Complaint further alleges that the Registration Statement omits material information concerning Aratana’s and Elanco’s financial projections and the analyses performed by Aratana’s financial advisor.

The problem with biopharmaceutical stocks is that they typically involve a high degree of risk. The research and development process for pharma companies often involves costly and lengthy clinical testing trials that yield specific data. If the expected data or end points are not met, the stock can drop drastically.

Without a strong understanding of the company and its basic operations, investors may be looking at serious losses.

Investigating Potential Claims

The White Law Group is investigating the liability that FINRA registered brokerage firms may have for improperly recommending high-risk biopharma stocks, like Aratana Therapeutics Inc. to investors.

Broker dealers are required to perform adequate due diligence on any investment they recommend and to ensure that all recommendations are suitable for the investor. Firms that fail to do so, may be held responsible for any losses in a FINRA arbitration claim.

These claims are distinct from the class action filed directly against Aratana and could be pursued concurrently.

If you have concerns regarding investment losses in Aratana Therapeutics Inc., please call the securities attorneys at The White Law Group for a free consultation at 888-637-5510.

The White Law Group, LLC is a national securities fraud, securities arbitration, investor protection, and securities regulation/compliance law firm with offices in Chicago, Illinois and Franklin, Tennessee.

For more information on The White Law Group and its representation of investors in FINRA arbitration claims, visit https://www.whitesecuritieslaw.com.

 

 

 

 

Comments are closed.